权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Glucolipotoxicity and Cardiac Dysfunction in Obesity

肥胖症中的糖脂毒性和心脏功能障碍

基本信息

批准号：
7262535
负责人：
HEINRICH TAEGTMEYER
金额：
$ 41.25万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-09-30 至 2009-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7262535
关键词：
2,4-thiazolidinedione Address Adipocytes Adipose tissue American Americas Animal Experiments Animal Model Apoptosis Attenuated Biopsy Blood Pressure Body Weight decreased Body mass index Bypass Cardiac Cardiac Myocytes Cardiomyopathies Cardiovascular Diseases Cessation of life Chronic Clinical Coronary heart disease Diet Disputes Dyslipidemias Echocardiography Environment Fatty Acids Fatty acid glycerol esters Functional disorder Gastric Bypass Gene Expression Genetic Glucose Glucose Intolerance Health Care Costs Heart Heart failure Hemostatic Agents Human Hypertension Insulin Resistance Intervention Lead Link Lipids Malonyl Coenzyme A Measures Metabolic Modeling Molecular Myocardial Nonesterified Fatty Acids Obesity Operative Surgical Procedures Organ Overnutrition Overweight Pathway interactions Patients Physiological Play Process Protein Glycosylation Protein Kinase C Proteins Rattus Reporting Research Personnel Resolution Risk Factors Role Skeletal Muscle Stomach Syndrome Testing Thiazolidinediones Thick Time Tissues Wistar Rats Zucker Rats bariatric surgery clinically relevant concept fatty acid metabolism fatty acid oxidation feeding food restriction indexing inhibitor/antagonist insight insulin sensitivity mortality nutrition oxidation programs protein activation response size statistics uptake

项目摘要

DESCRIPTION (provided by applicant): Alarming statistics on the spread of obesity include an increase in premature death from cardiovascular disease. Yet, the effects of over-nutrition on the heart are not well understood. We therefore propose to examine the "molecular footprints" of obesity in the heart, and identify mechanisms leading to impaired cardiac function in animal models, as well as in clinically obese patients undergoing gastric bypass surgery. Special emphasis is placed on the myocardial consequences of deranged glucose and fatty acid metabolism leading to a cardiomyopathy of obesity that is potentially reversible. The broad objective of this proposal is to test the hypothesis that abnormal accumulation of ,qlucose and fatty acid metabolites resulting from a loss of synchronization of substrate uptake and oxidation, induces glucolipotoxicity, and leads to contractile dysfunction of the heart. The first specific aim will define the process by which excess fuel supply (beyond the storage capacity of adipocytes) results in accumulation of lipotoxic compounds in the heart and in other organs (e.g. skeletal muscle). In genetic and diet-induced rat models of obesity we shall define the time course of adaptation and maladaptation to excess substrate availability. We shall also define the time course of reversal of obesity-induced changes by food restriction or surgical intervention (gastric bypass). The second specific aim will address potential mechanisms of glucolipotoxicity in heart, as well as in skeletal muscle. We shall examine gene expression, PKC activity, protein glycosylation, protein ubiquitinization, and programmed cell death. Selective activation of these different pathways may play a significant role in glucolipotoxicity. The third specific aim will apply insights gained from animal experiments to ascertain whether correlates of glucolipotoxicity exist in humans and test the hypothesis that weight loss reverses the maladaptive response in patients undergoing gastric bypass. We will define metabolic indices (BMI, insulin resistance, blood pressure, lipid profile, adipokine levels) and indices of cardiac function (by echocardiography) in tandem with skeletal muscle biopsies before, as well as three and nine months after surgery. Our Iong-term qoals are to define metabolic adaptation and maladaptation of the heart in clinically-relevant obesity, to transform the concept of glucolipotoxicity from an operational definition to a concrete physiological principle, and to establish a rationale for more effective treatment of obese patients with heart failure.

描述（由申请人提供）：关于肥胖症传播的令人震惊的统计数据包括心血管疾病导致的过早死亡的增加。然而，营养过剩对心脏的影响还没有得到很好的理解。因此，我们建议研究肥胖在心脏中的“分子足迹”，并确定导致动物模型心脏功能受损的机制，以及临床肥胖患者接受胃旁路手术。特别强调的是心肌的后果，紊乱的葡萄糖和脂肪酸代谢，导致心肌病的肥胖，这是潜在的可逆性。本提案的主要目的是检验以下假设：由于底物摄取和氧化同步性丧失导致葡萄糖和脂肪酸代谢物异常蓄积，诱导糖脂毒性，并导致心脏收缩功能障碍。第一个具体目标将定义过量燃料供应（超过脂肪细胞的储存能力）导致脂毒性化合物在心脏和其他器官（例如骨骼肌）中积累的过程。在遗传和饮食诱导的肥胖大鼠模型中，我们将定义对过量底物可用性的适应和适应不良的时间过程。我们还将确定通过食物限制或手术干预（胃旁路术）逆转肥胖引起的变化的时间过程。第二个具体目标将解决心脏以及骨骼肌中的糖脂毒性的潜在机制。我们将检测基因表达、蛋白激酶C活性、蛋白糖基化、蛋白泛素化和程序性细胞死亡。这些不同途径的选择性激活可能在糖脂毒性中起重要作用。第三个具体目标将应用从动物实验中获得的见解，以确定在人类中是否存在糖脂毒性的相关性，并测试体重减轻逆转接受胃旁路手术的患者的适应不良反应的假设。我们将在术前以及术后3个月和9个月确定代谢指标（BMI、胰岛素抵抗、血压、血脂、脂肪因子水平）和心脏功能指标（通过超声心动图），并与骨骼肌活检相结合。我们的长期目标是定义临床相关肥胖中心脏的代谢适应和适应不良，将糖脂毒性的概念从操作定义转变为具体的生理学原理，并建立更有效治疗肥胖心力衰竭患者的理论基础。